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Background and purpose 
In proton radiation therapy, the vast majority of patients have been treated using the passive 
scattering (PS) beam delivery technique. Increasingly, new proton therapy centers apply the 
pencil beam scanning (PBS) delivery technique instead of PS. PBS is generally considered to 
provide an increased sparing of surrounding healthy tissue and organs at risk (OARs). While 
a lot of clinical data is available for the PS modality, the original treatment plans does not take 
the linear energy transfer (LET) into account when calculating the relative biological 
effectiveness (RBE). Although the physical dose distributions for PBS and PS proton plans 
may be similar, the LET and RBE distributions could differ leading to potential different 
outcome from PBS compared to predictions based on clinical data from PS. The aim of this 
project was therefore to investigate whether or not a variable RBE negates the dosimetric 
benefits of PBS over PS.  
Materials and methods 
The various dose distributions were obtained using Monte Carlo (MC) simulations, which are 
the most accurate way of simulating particle interactions and dose deposition. Pencil beam 
algorithms used by treatment planning systems (TPS) do not take individual particle 
interactions into account. Instead, a particle beam is viewed as a composite of several thin 
beams, the dose distributions of which are based on measured data. In MC, accuracy is 
increased as every interaction is tracked for every particle. In this project, the MC code 
FLUKA was used. PBS treatment plans were created for three pediatric tumor patients 
previously treated with PS using the single-field uniform dose (SFUD) technique. This was 
done using the Eclipse TPS. Both the PS and the PBS treatment plans were stored in DICOM 
files, which is the standard format for storing medical imaging information and data in 
medicine. Relevant clinical data was extracted from these files and imported into FLUKA. A 
script which automated the creation of the PS input was developed using the Python 
programming language, while an inhouse script was used for PBS. The patients were imported 
into FLUKA using CT images stored in DICOMs, with an inhouse calibration curve being 
used to convert the grey-scale images into material and density information.  
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Dose distributions were calculated using both a fixed and a variable RBE, the latter of which 
required dose-averaged LET-distributions to be calculated. The resulting data were exported 
into DICOM files. The results were used to compare the biological dose distributions of PS 
and PBS, as well as the distributions calculated by MC and the TPS. The RBE-weighted dose 
delivered to both the target volume and the OARs were compared.  
Results 
The dose estimates calculated using the Eclipse TPS and FLUKA RBE1.1 agree well for all 
modalities, with differences below 2%. This confirms the correctness of the implementation 
of PS recalculations in FLUKA. The mean variable RBE values exceeded the clinically used 
RBE of 1.1 for all structures and patients. The doses calculated using the variable RBEs lead 
to an increase in dose to all structures, independent of the modality considered. This caused 
the dose constraints prescribed to the brainstem core to be exceeded for all patients and 
modalities, with the same being true for the brainstem for 2 out of 3 patients. The LETd values 
of PS were generally found to be greater than those of PBS, while the opposite was true for 
the RBE values. PBS exhibited a superior dose conformity for all dose calculation techniques, 
expressed through greater D05-D95 values and lower mean doses deposited to the OARs. 
Conclusions 
A variable RBE can lead to increased doses to OARs, especially at the distal ends of the 
treatment fields of both PS and PBS, where the LETd and RBE values increase the most 
significantly. While the mean RBE within all structures were either similar or greater for PBS, 
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The word “cancer” refers to a collection of diseases, all of which share a common trait: a few 
cells in the body start to divide uncontrollably and spread into nearby tissues. In contrast to 
healthy cells that die and divide according to the requirements of the human body, cancer cells 
can grow rampant and invasively, in addition to often having the ability of evading the immune 
system of the body. Although dependent on the type of cancer, these cells often accumulate 
into a cancerous tumor. Such tumors are considered malignant if they have the ability to spread 
to either nearby cells or organs, or to an entirely different area in the body [1]. 
Globally, every sixth death is caused by cancer, making it the second leading cause of death 
worldwide[2]. While there are a lot of ways to contract cancer, some of the most common 
include heavy tobacco or alcohol usage, an unhealthy diet and physical inactivity. Due to its 
high lethality, it is of utmost importance to both detect and treat the cancer as quickly and 
effectively as possible. Different types of cancer each requires a specific type of treatment, 
which could include surgery, chemotherapy or radiation therapy. The treatment could be 
palliative or curative [2]. 
1.1 Radiation Therapy 
X-rays were discovered by Wilhelm Rontgen in 1895, and already two months later they were 
used by Emil Grubbe to treat a patient with breast cancer. At this point, the physical properties 
of X-rays were not understood nor was the biological consequences of radiation. In 1898, 
however, Marie and Pierre Curie discovered radioactivity and their research into the 
physiological effects of radiation brought with it an increased number of studies focusing on 
the use of radiation in medicine. During the first few decades of the 1900s, significant research 
was made in the area of radiation therapy and the technique became increasingly more 
common. In 1928, the International Commission for Radiological Protection (ICRP) was 
established, which exists to address the question of radioprotection. The following decades 
were marked by continuous scientific development within the field of radiation therapy. After 
surgery, radiotherapy is today the second most effective curative cancer treatment. An 




Using accelerated charged particles for radiation therapy was first proposed in 1946. While 
the first patient was treated with particle therapy in 1956, the first hospital-based facility 
started operation in 1990 [5]. By this time, the medical efficacy of proton beams as opposed 
to photon beams had been studied. While both beams deposit energy as they traverse a 
medium, the manner in which they do it is different. Heavy charged particles, such as protons, 
will deposit an increasing amount of energy as it penetrates the material in question. This 
energy deposition will increase until it reaches a maximum, at which point the particle comes 
to a halt. The depth at which the particle stops depends on its initial energy as well as the 
medium and particle in question [6]. Photons, on the other hand, cannot decrease in velocity. 
Instead, the intensity of the beam itself weakens as it penetrates a medium. This makes sparing 
of healthy tissue difficult when delivering a substantial dose to the target volume. How fast a 
photon beam is absorbed depends on the medium [7]. The depth-dose curves of photons, 
protons and carbon are illustrated in Figure 1.1. 
 
Figure 1.1: Photon and proton depth dose curves taken from [8].  
Although the area of maximum dose deposition, i.e. the “Bragg peak”, is rather narrow for 
protons, it is possible to weight the particle fluences within the beam as desired. This makes it 
possible to deliver a homogeneous dose to the entire target with a single field. It is common, 
however, to use multiple fields, as this decreases the dose received by healthy tissues. Using 
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multiple beams is a necessity in photon therapy, as delivering a homogeneous dose to the 
target cannot be done with a single beam [9].   
The relative biological effectiveness (RBE) is the ratio between the doses required by two 
different types of radiation in order to achieve the same biological effect. Prescription doses 
are defined as photon doses in order to maintain clinical consistency. The biological proton 
dose is found by multiplying the photon dose with the RBE of protons. Following a series of 
experiments in the 1960s, a constant RBE of 1.1 was assigned to protons. This is a conservative 
estimate made to avoid any underdosages. In reality, the RBE is variable and depends on 
several factors, one of which is the linear energy transfer (LET). The LET, itself a variable, is 
a measure of the energy deposited along the track of a charged particle which interacts 
electromagnetically [10].    
There are two main modalities in proton therapy: passive scattering (PS) and pencil beam 
scanning (PBS). The former works by conforming the proton beam to the target volume within 
the beamline geometry, while the latter sequentially scans a thin beam across the target using 
magnets. Although PS has been in use the longest, PBS is becoming increasingly more 
common due to its superior flexibility and dose conformity [5].  
1.2 Monte Carlo Simulations 
The biological effect of radiation on human tissues is, for both ethical and practical reasons, 
challenging to investigate. While a treatment planning system (TPS) is used to create treatment 
plans, the dose distributions calculated by such systems tend to be somewhat inaccurate. The 
algorithm used by a TPS does not take individual particle interactions into account. Instead, a 
particle beam is divided into narrow beams. The dose contribution of each beam is calculated 
based on experimental beam data, making the results a compromise between accuracy and 
computation time [11].  
Monte Carlo (MC) simulations are considered the most accurate way of calculating dose 
distributions in radiation therapy, as it is based on real physical models and experimental data. 
By tracking the physical interactions of each and every particle in the beam, a great amount of 
accuracy can be achieved with MC. The computation time required does, however, increase 
as the simulation environment becomes more complex. Uncertainties in MC calculations are 
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inversely proportional to the root of the number of particles simulated. While increasing the 
number of particles will increase the accuracy, it also brings with it an increase in computation 
time. This makes MC inefficient for use in the clinic [12]. 
The algorithms used by a TPS does not take the position of tissue inhomogeneities along the 
beam path into account. Instead, the dose is calculated along the beam axis using dose-to-
water kernels, which are functions of water-equivalent depth. Ignoring the positions of 
heterogeneities relative to the Bragg peak can have a significant impact on the estimated beam 
range [13]. An MC code, on the other hand, takes specific material properties into account. 
Using real theoretical models and experimental cross-section data, particles are accurately 
tracked throughout the entire geometry, secondaries included. In addition to being able to 
calculate the dose-to-material for a range of particles, MC can calculate a variety of quantities, 
for instance an LET-distribution. While MC codes are very useful in radiotherapy, they are 
general tools used in a variety of fields [11, 13].     
1.3 Project Objectives 
Whereas the majority of patients so far have been treated using PS, many current and most 
future patients will be treated with PBS. The aim of this study was therefore to investigate 
differences between the techniques with respect to LET and RBE distributions. This is also 
necessary to enable knowledge transfer including biological dose from previously treated 
patients to future treatment techniques. Dose distributions were calculated for both treatment 
modalities using both a fixed and a variable RBE using the FLUKA MC code [14, 15]. Setting 
up the simulation environment required inhouse scripts which define the various beamline 
geometries, as well as the importation of patient specific data based on treatment plans for the 
PBS modality. A script was developed for the importation of PS data, from which the beamline 
could be defined. TPS dose distributions were also calculated in order to make comparisons 
with the FLUKA distributions. 
Chapter 2 contains descriptions of how charged particles interact with matter. This chapter 
also contains some radiobiology, which includes dosimetry, the linear-quadratic model, linear 
energy transfer and relative biological effectiveness (fixed and variable).  
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Chapter 3 describes the treatment process, from imaging to treatment. This includes a 
description of CT, the delineation process, the various accelerators, the treatment room, as 
well as the two main proton therapy modalities. Additionally, a general description of MC is 
provided here. 
Chapter 4 describes the methods used, more specifically how the MC simulations were 
created. This includes a basic introduction to FLUKA, along with the key components 
necessary for the simulations.  
Chapter 5 presents the results as found through the methods described in chapter 4.  




 Physics of Particle Therapy 
2.1 Charged Particle Interactions in Matter 
Understanding how heavy charged particles interact with matter is integral to the field of 
particle therapy. Protons, the primary particles considered in this project, moving through a 
material will interact through three distinct processes: electromagnetic interactions with the 
atomic electrons, electromagnetic interactions with the atomic nuclei and non-elastic 
collisions with nuclei. The former two processes are well understood, while the effects of the 
latter can be taken into account through simple approximations [16].  
2.1.1 The Bethe-Bloch Equation 
A heavy charged particle traversing a material will mainly lose energy through 
electromagnetic interactions with bound electrons, a process which ionizes and excites the 
material in question. This energy loss is typically referred to as the stopping power of the 
charged particles. The resulting ionized electrons may cause further ionizations in the medium, 
provided they receive enough kinetic energy from the collision with the traversing particle.  
Such electrons are referred to as d-electrons. The energy loss per collision is often quite small, 
typically less than 100 eV, making d-electrons with even modest energies rare. There is, 
however, typically a large amount of collisions per unit path length, making this an efficient 
mode of energy deposition in all but the thinnest layers of matter. The stopping power of a 





















• 𝐾 = 4𝜋𝑁&𝑟"!𝑚"𝑐! ≈ 0.307MeVg-1cm2 
• z = charge of the traversing particle in units of electron charge 
• Z/A = ratio of the atomic number to the atomic mass of the traversed medium 
• b = velocity of traversing particle in terms of c  
• c = speed of light in a vacuum  
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• me = the electron mass 
• g = Lorentz factor 
• I = mean excitation potential 
• Wmax = maximum energy transferred in a single collision 
• d(bg) = density effect correction 
• C = shell correction 
 
The mean excitation potential is a variable which depends on the material in question and it 
cannot be calculated to sufficient accuracy using first principles. Instead, it is usually estimated 
from experimental measurements of stopping power and interpolation can be used for 
materials where such measurements do not exist. The mean excitation potential is 
approximately proportional to the atomic number of the absorbing material multiplied by 10 
eV [6, 16]. Finding the maximum energy transferred in a single collision is, on the other hand, 
more straightforward. For a traversing particle of mass M, Wmax is given by [6]:  
𝑊#$% =
2𝑚"𝑐!𝛽!𝛾!




For charged particles with relativistic energies, a divergence between the real energy loss and 
the stopping power calculated by Bethe-Bloch occurs. This divergence increases with higher 
energy and denser material. The density effect correction, d(bg), was added to the formula in 
order to account for this. This correction term becomes relevant at energies much higher than 
those used in particle therapy, typically at >1-2 GeV, while the energies used in proton therapy 
is in the 3-300 MeV range. The density correction is therefore typically ignored [16, 17].  
In Bethe-Bloch, the velocity of the charged particle is required to be much larger than the 
velocity of the bound electrons. While this requirement is fulfilled for high particle energies, 
it could lead to an error of up to 6% in the 1-100 MeV range. This possible offset is corrected 
by the shell correction term [17]. 
The Bethe-Bloch equation is only valid as long as the traversing particle has an energy which 
is large compared to the energies of the bound electrons. While corrections can be added to 
the equation, making it possible to have an error below 1% down to 1 MeV, approximations 
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and phenomenological fitting formulas must be used to calculate the stopping power in these 
low energy regions [6]. 
2.1.2 Scattering of Particles 
Charged particles moving through a material will not follow straight trajectories. Instead, they 
will undergo many small-angle deflections. These deflections are caused by the Coulombic 
interactions between the incoming particle and the nuclei of the material. This process is called 
multiple Coulomb scattering (MCS), and it leads to a lateral broadening of the beam. Because 
the scattering is the sum of many tiny stochastic deflections, the resulting angular distribution 
is very nearly Gaussian, with the deviation being the result of single large deflections which 
occur not quite infrequently enough. The Gaussian part of the distribution contains 
approximately 98% of the protons, which can be used for most radiotherapy purposes. There 
are several models available for calculating the MCS angular distribution, with Molière’s 
theory being considered the most comprehensive and accurate for protons. Knowing the lateral 
broadening of the particle beam is of great importance in particle therapy, as it will affect the 
area of energy deposition [16]. 
2.1.3 Nuclear Interactions 
The incoming particles will sometimes undergo inelastic collisions with nuclei in the 
absorbing medium. When this happens, the traversing particle will knock lose one or more 
proton, neutron or light nucleon cluster. The resulting nuclear fragments tend to have much 
lower energies and much larger angles than the incoming particle [16]. These particles will 
contribute to the total dose and their point of energy deposition might be outside the target 
volume. The latter point is of special importance when considering neutral nuclear fragments, 
as these do not interact electromagnetically and might therefore travel beyond the range of the 
primary particles [18].  
2.1.4 Straggling and Range 
Due to the statistical fluctuations associated with charged particle interactions in matter, 
determining the range of a particle beam in a given material brings with it some difficulties. 
A charged particle will lose energy in a series of discrete steps, leading to a variation in the 
particle range. This phenomenon is called straggling. Knowing the range of the particles used 
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in radiotherapy is of great importance, as uncertainties could lead to decreased target coverage 
and increased healthy tissue irradiation. The mean range of the particles can be found 
theoretically with the continuous slowing down approximation (CSDA). The CSDA range is 
obtained by integrating the reciprocal of the total stopping power from its maximum energy, 
E, to 0 [6, 16]. On the other hand, if one assumes that the energy-range relationship can be 
described by a power law, an analytical approximation can be calculated. Such approximations 
have been found to lead to deviations of maximum 5% when compared to measurements and 
numerical approaches [19].  
2.1.5 The Bragg Curve 
The inverse velocity dependency of the Bethe-Bloch equation means that the stopping power 
of a traversing particle will increase with decreasing energy. This will continue until a point 
of maximum energy deposition, where the particle will deposit the rest of its energy and come 
to a halt. The Bragg curve, which plots the stopping power of charged particles in matter as a 
function of depth, therefore has a characteristic peak. Beyond this peak, which is called the 
Bragg peak, the energy deposition of the particles should instantly fall to zero, which is indeed 
the case for a single particle. However, when multiple particles are considered, a small tail 
becomes present on the Bragg curve, due to straggling. At which depth the Bragg curve occurs, 
i.e. the range of the particles, depends on the incident particle energy [16]. An example of a 




Figure 2.1: Example of a Bragg peak. Taken from [20]. 
 
As illustrated in Figure 2.1, the Bragg peak is rather narrow. However, by combining Bragg 
peaks of different ranges, and weighting them appropriately, one can create a spread-out Bragg 
peak (SOBP). SOBPs are useful in particle therapy, as their width can be chosen as desired. A 
particle beam can thus be conformed to the target volume in the longitudinal direction. An 




Figure 2.2: Example of a spread-out Bragg peak, taken from [16]. 
2.2 Dosimetry 
Ionizing radiation passing through a material will deposit energy. In radiotherapy, it is of great 
importance to be able to determine exactly how much energy is received by a biological 





where DE is the mean energy deposited by ionizing radiation to a mass Dm. Absorbed dose is 
measured in Gray (Gy) in the SI system, with 1 Gy = 1 J/kg. Not all the energy lost by an 
ionizing particle will contribute to the dose, as some energy will be lost to secondary particles, 
such as neutrons and photons, which might deposit their energy outside the patient [16].  
A unit dose deposited by one type of radiation might not have the same biological effect on a 
certain tissue as another type of radiation depositing the same dose. A weighting factor was 
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introduced in order to differentiate between different types of radiation, and the equivalent 




where 𝑤( is the weighting factor for the type of radiation in question, and 𝐷',( is the dose 
averaged over all types of tissue. The unit for equivalent dose is the Sievert (Sv), where 1 Sv 
equals 1 J/kg. The weighting factors for the various types of radiation are defined by the 
International Commission on Radiological Protection (ICRP) [21]. These are shown in Table 
2.1. 
Table 2.1: Radiation weighting factors as recommended by the ICRP [21]. 
Radiation type  Radiation weighting factor, wR 
Photons  1 
Electrons and muons  1 
Protons and charged pions  2 
Alpha particles, fission 









2 ,																																					𝐸- < 1𝑀𝑒𝑉	
5.0 + 17.0𝑒*
[,-(!/!)]"
2 , 						1𝑀𝑒𝑉 ≤ 𝐸- ≤ 50𝑀𝑒𝑉
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The equivalent dose does not take the type of irradiated tissue into consideration. The effective 
dose was introduced to include weighting factors for the various types of tissue. The effective 








where 𝑤' is the weighting factor for the type of tissue in question. The unit for effective dose 
is also the Sievert [21]. The weighting factors are again determined by the ICRP and are shown 
in Table 2.2. 
Table 2.2: Tissue weighting factors as recommended by the ICRP [21]. 
Tissue 𝒘𝑻 ∑𝒘𝑻  
Bone-marrow (red), Colon, Lung, Stomach, 
Breast, Remainder tissues 
0.12 0.74 
Gonad 0.08 0.08 
Bladder, Oesophagus, Liver, Thyroid 0.04 0.16 
Bone surface, Brain, Salivary glands, Skin 0.01 0.04 
 
2.3 Radiobiology 
The goal of radiation therapy is to irradiate cancer cells using as much ionizing radiation as 
possible, while simultaneously minimizing the damage to healthy cells. It is therefore of great 
importance to know how radiation affects living tissue. Radiobiology combines the fields of 
physics and biology and studies the effects of ionizing radiation on biological cells. A cancer 
cell is considered killed when it loses its reproductive ability. A cell can become unable to 
proliferate if its DNA molecules gets damaged.  
Charged particles are directly ionizing, which means that they are able to directly damage the 
DNA. Direct damage to the DNA, which is called “direct action”, would typically lead to 
either a single- or a double strand break (SSB and DSB, respectively). Although SSBs are 
easily repaired by the cell, they can cause a DSB if they happen in close proximity to each 
other. DSBs are much more difficult to repair than SSBs and will ideally make the cell unable 
to proliferate.  
For protons in the energy range 0.5-100 MeV, ~70% of the energy lost will be transported 
away by the d-electrons they produce. These electrons might then ionize further, as well as 
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cause further strand breaks. Charged particles can also cause indirect damage to the DNA-
strands by creating free radicals through interactions with the water inside the cell. These free 
radicals can then damage nearby DNA. At low LET, most of the damage done to DNA is 
through indirect action. The effects of direct action becomes more pronounced with increasing 
LET [10]. Figure 2.3 illustrates both direct and indirect action. 
 
Figure 2.3:  Direct and indirect action. Modified from [10]. 
2.3.1 The Linear-Quadratic Model 
In the linear-quadratic model (LQ model), the survival probability of an irradiated cell is given 
by the following equation:  
𝑆 = 𝑒*9:*;:" (2.6) 
where D is the exposure dose, and a and b are the linear and quadratic parameters, 
respectively, which describe the radiosensitivity of the cells in question. Plotting cell survival 
on a log scale yields a dose-response curve, as illustrated in Figure 2.4. The a/b-ratio, which 
is given in Gy, is defined as the dose where both components of equation 2.6 contribute equally 
to the cell killing. The ratio describes the curvature of the cell survival curve, with a lower 
ratio corresponding to a greater curvature. The a/b-ratio depends on the type of irradiated 




Figure 2.4: Example of dose-response curve. Taken from [22]. 
A high a/b-ratio (7-10 Gy) typically characterizes early responding tissue, while a low a/b-
ratio (3-5 Gy) corresponds to late responding tissue. The cell survival curve of an early 
responding tissue is less curved than for late responding tissue. This means that while the 
former sees a relatively constant rate of cell killing with increasing treatment fractions, the 
latter does not. Rather, the surviving fraction of late responding tissue decreases more 
significantly as the dose increases. Malignant tumors tend to have a high a/b-ratio, which 
means the rate of cell killing will be relatively constant. Splitting the dose into several smaller 
fractions can therefore increase the sparing of healthy tissue with a lower a/b, such as lungs, 
the brainstem and the heart [22, 23]. 
2.3.2 Linear Energy Transfer 
Linear energy transfer (LET) is a measure of the energy deposited to a medium along the track 







LET is the amount of energy deposited per unit length, with a greater value corresponding to 
a greater ionization density along the particle trajectory. Its unit is keVµm-1 [7]. For heavy 
charged particles, the LET value increases greatly with decreasing energy, which is to be 
expected from Figure 2.1.  
Equation 2.7 describes what is called the unrestricted LET (LET∞), which is the total 
electronic stopping power. This quantity can be used to calculate the absorbed dose, which at 
a given point is the product of the electronic stopping power and the particle fluence. Because 
the LET varies over the particle track, it is beneficial to use averaged LET values. The dose 
averaged LET (LETd) is the most commonly applied LET in radiation therapy, as it takes both 














where E is the energy of the primary charged particles, Sel(E) is the electronic stopping power, 
i.e. the unrestricted LET, D(E, z) is the absorbed dose deposited at point z, and F(E, z) is the 
fluence of the particles at a point z. Figure 2.5 illustrates how the LET increases with depth. 
 
Figure 2.5:  Dose-averaged LET for primary particles (solid line) and for all particles (dashed line). 
The dotted line represents dose. Taken from [10]. 
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2.3.3 Relative Biological Effectiveness 
When assessing the biological effects in radiation therapy, the ICRP does not recommend 
using the radiation and tissue weighting factors described in chapter 2.2, as these were 
primarily intended to be used for radiation protection [21]. Instead, the biological effectiveness 
of a given type of radiation can be calculated using the relative biological effectiveness (RBE) 
and the absorbed dose. RBE is defined as the ratio between a reference dose Dx and a dose D, 





Due to a large amount of clinical data, and to maintain clinical consistency, 250 kV x-rays are 
typically used as the reference radiation type. The RBE is used to convert physical dose to 
biological dose, i.e. RBE-weighted dose [7]. In proton therapy, a constant RBE of 1.1 has been 
used. However, it has been shown that this value might not be entirely correct [23, 25]. While 
an RBE of 1.1 seems reasonable for low LET-values, an increase in LET leads to an increase 
in RBE as well. This relationship is illustrated in Figure 2.6. As the figure shows, at around 
100 keVµm-1 the RBE reaches a maximum, a point beyond which the RBE declines due to an 
increasingly inefficient ionization density [7]. 
 
Figure 2.6: The relationship between RBE and LET in mammalian cells for different cell survivals 
(S). Taken from [7]. 
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There are several proposed models which give a varying RBE-value by taking values such as 
LETd and tissue type into account [25]. Using the LQ model, one can obtain a general 




























where ax and bx are the LQ parameters which describe the reference radiation, and ap and bp 
describe the proton radiation. The reference parameters are obtained using clinical data, while 
the manner in which the proton parameters are obtained depends on the RBE model used.  
Using a variable RBE, as opposed to a fixed RBE, is predicted to not only affect the dose 
received by the target volumes, but by any potential nearby OARs as well. This might 
especially be the case for any OARs located close to the end of the particle beam range, as the 
LETd increases significantly here. Additionally, a variable RBE might introduce hot and cold 
spots in the target area, which could negatively affect the prescribed target coverage [23, 25].  
The variable RBE model used in this project was the McNamara model, in which the proton 




















 Treatment Planning and Delivery 
The treatment planning process is one of the most important elements of radiation therapy and 
consists of several multidisciplinary steps, where clear and ongoing communication is 
necessary. Treatment planning requires not only clinical information, anatomical data and 
dose prescriptions, but also an understanding of the limits and possibilities of the various 
treatment modalities [27].  
The aim of the planning process is to design a plan which delivers as high a dose as possible 
to the target volume, while simultaneously minimizing healthy tissue complications. Meeting 
the dose prescriptions and constraints given to the target volume and the OARs might not be 
possible at the same time, however. This makes the treatment planning process one of 
compromise.  During treatment planning, two dose-response curves are of great importance: 
the tumor control probability (TCP) and the normal tissue complication probability (NTCP) 
[27]. These curves, illustrated in Figure 3.1, plot their respective probabilities as a function of 
dose.  The area between the two curves is known as the therapeutic window. A critical 
objective in radiotherapy is to increase the size of this window, thus reducing potential healthy 
tissue complications.  
 
Figure 3.1: TCP, NTCP and the therapeutic window. Taken from [18]. 
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3.1 Treatment Planning 
3.1.1 Image Acquisition 
The first part of the treatment planning process is to obtain anatomical images of the patient. 
The images are needed in order to accurately assess the size and position of the target volume, 
as well as any potential organs at risk [27].  
The imaging gold standard in radiotherapy is computed tomography (CT), as this modality 
allows for the acquisition of tissue density information. CT is an X-ray imaging procedure in 
which a beam of X-rays is continuously scanned around the patient in a helical fashion, 
producing a series of cross-sectional images of the patient. The continuous scanning leads to 
fewer motion artefacts, in addition to shorter scanning time. The image-slices, an example of 
which is shown in Figure 3.2, are digitally stacked together, yielding a three-dimensional 
image of the patient [28]. 
 
Figure 3.2: Example of a CT image showing the heart and lungs. Darker areas correspond to low 
density tissue (such as the lungs) and lighter areas correspond to high density tissues (such as the 
heart). Taken from [28]. 
Electromagnetic radiation moving through a medium will decrease in intensity. The degree of 
attenuation depends on the medium in question and is expressed through the linear attenuation 
coefficient, µ, associated with the given material. This is expressed through equation 3.1. 
𝐼(𝑥) = 𝐼5𝑒*?% (3.1) 
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where Io is the initial beam intensity, I(x) is the final intensity, x is the absorber thickness and 
µ is the linear attenuation coefficient. The differently attenuated X-ray images are stacked 
together into a gray scale CT image, in which darker areas correspond to low density tissues 
and vice versa [28].  
3.1.2 The Hounsfield Unit 
Gray-scale CT images are generated by assigning a Hounsfield Unit (HU) to areas of different 
attenuation, i.e. tissue density. The HUs, which are dimensionless, are calculated and assigned 
a voxel by linearly transforming the linear attenuation coefficients using equation 3.2: 




As can be seen from the equation, water is defined to have HU=0. Additionally, air is defined 
to have HU=-1000. The HUs are assigned a gray-scale intensity, with greater numbers 
corresponding to brighter areas, from which a gray-scale image can be formed. HUs can be 
transformed into relative stopping power values needed for range calculations in proton 
therapy [28, 29]. This is done by using a CT calibration curve, which like the HUs are machine 
specific. The most common way of acquiring such a curve is the stoichiometric method, which 
makes use of a phantom comprised of tissue surrogates of known elemental compositions. 
These surrogates are then scanned and the resulting HUs are used to obtain a calibration curve 
through linear regression [30].  
3.1.3 Regions of Interest 
After scanning the patient, the acquired images are given over to a radiation oncologist. They 
will locate and mark the positions of the various volumes of interest, such as the target volume 
and potential organs at risk (OARs). The various targets and volumes which are used in 
radiation therapy are defined in ICRU Report 50 [3]. 
The gross target volume (GTV) is the volume which most closely encompasses the 
macroscopic target tumor volume. The position, extent and shape of the GTV is typically 
determined by studying images acquired through medical imaging, but these properties might 
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also be found through clinical examination. The GTV should receive a high dose to its entire 
volume, as it will have a large tumor cell density [27, 28].   
The clinical target volume (CTV) includes the GTV with an added error margin. Not all 
malignancies are detectable in the clinic, and tumor cells might extend beyond the borders of 
the GTV. The CTV encompasses the area where proliferative tumor cells are expected to be. 
This entire volume must be adequately irradiated in order to cure the malignancy [3].  
The GTV and the CTV are both delineated without any regard for patient movement, range 
inaccuracies or other errors in the setup. The planning target volume (PTV) takes such 
potential problems into account by adding an extra margin of error around the CTV. This 
minimizes the discrepancies between the planned and delivered dose received by the CTV [3]. 
The different target volumes are shown in Figure 3.3.  
 
Figure 3.3: The different target volumes. Taken from [3]. 
In addition to delineating the target volume, it is of high importance that the various OARs are 
marked as well. OARs include nearby healthy tissues and organs with high radiosensitivity 
that needs to be spared. In order to achieve maximum sparing, the OARs are delineated with 
an extra margin, like the CTV and the PTV [28].  
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Once the relevant structures have been delineated, the dose planning process can begin. In 
addition to delineating the various regions of interest (ROIs), the physician also provides a 
dose prescription to be delivered, as well as dose constraints for the OARs. These are then 
entered into the treatment planning system (TPS) [27].   
3.1.4 The Treatment Planning System 
Once the relevant structures have been delineated and assigned a dose prescription and 
constraints, a treatment plan can be created.  This can be done using a TPS, with which it is 
possible to determine a three-dimensional dose distribution to be delivered to the patient. 
Using the clinical information, which is imported into the TPS, a virtual representation of the 
patient can be created, delineated structures included. The aim of the treatment plan is to 
satisfy the prescription to the target volume as accurately as possible, while delivering as little 
dose as possible to the OARs and healthy tissues. The dose constraints prescribed for the 
OARs are upper limits, and the goal is to minimize the dose to these volumes. It is often 
difficult to meet all these criteria exactly, however, due to the constraints stemming from the 
size of the therapeutic window. This is especially true when there is more than one OAR to 
consider. Additionally, certain OARs might be assigned dose constraints which are not to be 
exceeded under any circumstances [27]. 
While a proton beam is able to deliver the entire dose prescription homogeneously to the target 
volume from only one direction, it is common to use multiple fields. This way, increased 
sparing of healthy tissue is achieved. How the treatment fields are optimized depends on which 
proton therapy modality is chosen, i.e. passive scattering (PS) or pencil-beam scanning (PBS). 
Both of these modalities are explained in more detail in section 3.3, but in short: PS irradiates 
the entire target at once after conforming the beam in the beamline, while PBS sequentially 
scans over the target with a thin beam. The former is less flexible than the latter, as PBS has 
the ability to deliver a much more heterogeneous dose distribution. This makes it possible to 
increase healthy tissue sparing, in addition to allowing for intensity modulated proton therapy 
(IMPT) [27].  
In IMPT planning, multiple fields are optimized simultaneously using the prescribed dose 
constraints. When using such multi-field optimization (MFO), the fluence of each pencil beam 
is optimized at the same time. This means that while the total dose delivered to the target will 
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be homogeneous, the contribution from each field might not be. Inverse optimization is a 
gradient-based, iterative process, in which a series of plans is generated based on the given 
dose objectives and constraints. These plans are automatically assessed, and the best one is 
chosen. This plan will still require an assessment by the treatment planner [31, 32].  
A PS plan is not made using inverse treatment planning. Instead, treatment plans are created 
using the single-field uniform dose (SFUD) technique, in which each field delivers a 
homogeneous dose to the target. These fields are designed individually before being linearly 
added together. SFUD can be used for both PS and PBS, with the latter achieving a better dose 
conformity to the target, as well as increased sparing of healthy tissue. This is because PBS 
can weigh the individual pencil-beams as required [27].  
Clinical planning systems calculate dose distributions using analytical pencil beam algorithms, 
which treat proton beams as composites of a set of narrow pencil beams. The dose deposition 
is calculated along the axis of each pencil beam, using experimentally measured depth-dose 
curves and lateral beam profiles. The contributions of each pencil beam are then added 
together, resulting in a complete dose calculation for the patient [13, 31].  
3.1.5 Treatment Plan Assessment 
Before being used for treatment, every treatment plan needs to be assessed by the radiation 
therapist. This can be done directly in the TPS. The dose distribution can be visually inspected 
using an isodose distribution or a color wash overlaid on the CT images with a well-defined 
color bar, in which warmer colors typically represent areas of higher dose and vice versa. The 
dose conformity can be found using isodose curves, which are contours marking regions to 
which a particular dose percentage is delivered [28]. Such visual displays, while helpful, are 
not enough to properly evaluate a treatment plan, as it provides no information about the dose 
received by the various structures. This information can be acquired by using a dose volume 
histogram (DVH), which shows how much dose is received by a given percentage of a 
structure of interest. DVHs do not, however, contain any information about the dose 
conformity [33].  
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3.2 Particle Accelerators 
The energies used in particle therapy is of such a magnitude that a particle accelerator is 
necessary. There are two main types of ion accelerators: cyclotrons and synchrotrons [34]. 
Cyclotrons, an example of which is illustrated in Figure 3.4, are circular and the particles that 
are to be accelerated start out at the center. Using magnetic fields and a rapidly varying electric 
field, the particles are accelerated in an outward spiral until they reach the maximum energy 
allowed by the cyclotron, at which point they are extracted. The advantage of a cyclotron is 
the ability to deliver a continuous beam of particles, which a synchrotron is unable to do. A 
disadvantage of cyclotrons is that they can only accelerate the particles to a fixed energy due 
to the nature of their design. Additionally, they are poorly suited for ions heavier than protons. 
Cyclotrons typically accelerate protons up to the energy range of 230-250 MeV, which is at 
the upper end of the energies typically used in proton therapy. Lower energies can be achieved 
through energy modulation, which for cyclotrons has to happen after the extraction of the 
particle beam. This way of modulating the energy beam is called passive modulation and 
works by putting a degrader in front of the beam. This can be done immediately after extraction 
or within the treatment nozzle itself [34]. 
 




Synchrotron accelerators, an example of which is illustrated in Figure 3.5, are much larger 
than cyclotrons, and they have the ability to achieve much higher energies. One or more linear 
accelerators must be part of the particle injection system, as the particles need to be accelerated 
to a few MeV before being inserted into the synchrotron. The synchrotron itself is circular, or 
close to circular, and consists of a large evacuated tube and strong magnets used for bending 
the particle trajectories as well as for beam focusing. By adjusting the magnetic field strength 
in a synchrotron, it is possible to vary the energies to which particles are accelerated within 
the accelerator itself, which is called active modulation. A disadvantage of synchrotrons is its 
inability to quickly extract the particle beam [34]. 
 
Figure 3.5: Illustration showing how synchrotrons work. Taken from [28]. 
3.3 Particle Therapy Modalities 
Once the particle beam has been accelerated it needs to be conformed to the target volume. As 
mentioned above, the two major delivery techniques in particle therapy are called passive 
scattering (PS) and pencil beam scanning (PBS) The former modality is the oldest and is 
historically the most widespread, although the latter is becoming more common. While these 
modalities may have some commonalities, such as ionization chambers used for beam 
monitoring [29], their geometry is quite different. 
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3.3.1 Passive Scattering 
PS works by first spreading the beam in both the lateral and longitudinal direction. In the 
lateral direction, this is commonly done using one or two scatterers (referred to as the first and 
second scatterer, respectively) of high-Z material, such as lead or brass. The first scatterer is 
typically thin and flat and is used for spreading the beam onto the second scatterer, provided 
it is not a single scatterer system. Second scatterers can have a variety of configurations, some 
of which are shown in Figure 3.5, and aim to spread the beam out as uniformly as possible. 
One example is the contoured scatterer, which is thicker at the center and thinner at the edges. 
A low-Z material is often applied to the second scatterer for energy compensation. This is 
done to make sure the energy, and thereby the range, is equal across the lateral beam 
distribution [35]. Additionally, variable collimators can be included in order to reduce the 
proton fluence in the beamline geometry, as this could lead to an increased neutron background 
[36]. 
 
Figure 3.6: Various possible configurations of scatterers. Taken from [35]. 
Spreading the beam out longitudinally is done by creating a spread-out Bragg peak (SOBP). 
This is done by applying a range modulation technique, such as utilizing a ridge filter or a 
range modulation wheel (RM wheel), with the latter being the most commonly used. By 
having different parts of the beam move through low-Z material of different thickness one 
produces several Bragg peaks [36]. The individual Bragg peaks can be weighted as desired, 
28 
 
and together they create a SOBP. For an RM wheel this is achieved by rotating a wheel 
consisting of different steps in front of the particle beam, with each step having a certain 
thickness. The widths of the steps are chosen such that the SOBP is as flat as possible, making 
each RM wheel usable for a very small range of beam energies. If the desired modulation 
width is thinner than the widest one allowed by the RM wheel, only parts of the wheel needs 
to be irradiated. This can be achieved by either turning the beam on and off, synchronized with 
the wheel rotation, or by covering parts of the wheel so that particles are unable to pass 
through. This makes it possible to use the same RM wheel for several modulation widths. 
Additionally, by using beam current modulation (BCM), a complex feedback technique, one 
can alter the beam current and achieve a flat SOBP for an even wider range of energies per 
RM wheel [37].  
Once the beam has been spread out both laterally and longitudinally it needs to be conformed 
to the target volume. An aperture is used to conform the beam in the lateral direction. The 
shape of the aperture is defined by the back projected shape of the target volume, using extra 
margins which account for uncertainties in penumbra and setup. The aperture is made from a 
high-Z material, such as brass, due to the large stopping power required [35].  
Conforming the dose to the target volume in the longitudinal direction requires a range 
compensator. Such compensators are designed to remove the depth variation by adding more 
absorbing material in areas of smaller depth and less material in areas of greater depth. A low-
Z material is used to ensure low scattering. Like the aperture, the compensators have to be 
unique for each treatment field [35, 36]. The complicated setup illustrates one of the 
drawbacks of PS. Each field requires a unique aperture and compensator, in addition to a 
specific configuration of scatterers and range modulators. Another drawback is that protons 
will interact with the scattering and range modulation materials, which leads to energy loss, 
the creation of secondary particles and angular diffusion, which increases the lateral penumbra 
of the beam. PS is, however, quite robust and requires less sophisticated systems than PBS. 
Additionally, the whole target is irradiated semi-instantaneously, making PS less sensitive to 




Figure 3.7: Illustration of the passive scattering technique. Taken from [18]. 
3.3.2 Pencil Beam Scanning 
PBS requires fewer components than PS, as the beam is not passively spread out before 
delivery. Instead, a pair of dipole magnets are used to steer the beam in both the horizontal 
and vertical direction. The strengths of their respective fields are adjusted during treatment, 
making the sequential scanning possible in the lateral direction [38].  
By varying the energy, different depths of dose deposition are achieved. The beam can thus 
be scanned over the target volume, slice by slice. The scanning can either happen discretely, 
meaning the beam is turned on and off between each voxel, or it can scan continuously over a 
layer. It is of great importance to know the various beam parameters during scanning, so 
feedback systems and precise beam control needs to be in place for this modality. Active 
scanning is more efficient than PS as it requires no patient-specific hardware. This also means 
that the beam interacts with less material before it reaches the target, creating fewer 
secondaries. A higher dose conformity to the target and increased sparing of healthy tissue is 
also achieved with PBS, as each beam can be weighted as required. Additionally, PBS is more 





Figure 3.8: Illustration of pencil beam scanning. Taken from [18]. 
3.4 The Beam Profile 
Regardless of the chosen treatment modality, an aim of proton therapy is to deliver as 
conformal a dose as possible to the target. One way to assess whether or not this is achieved 
is by looking at the dose distributions in the lateral and longitudinal direction. Both 
distributions can be described by specific parameters, also called “dosimetric indices”. Figure 
3.9 illustrates various dosimetric indices used to describe the SOBP dose distribution, i.e. the 
depth-dose distribution, with the dose being normalized to 100% at the dose plateau. 
 
Figure 3.9: Depth-dose distribution. Modified from [9]. 
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Here, the dosimetric indices define the depth at which specific dose levels are found, with the 
prefixes referring to the proximal and distal ends of the beam (“p” and “d”, respectively).  For 
example, the p90 parameter refers to the proximal depth at which 90% of the dose is delivered. 
The most clinically relevant parameters, i.e. the range and modulation width, are typically 
defined by d90 in the former case, and by the distance between p90 and d90 in the latter case. 
However, some radiotherapy clinics rather use d80 for range and/or define the distance 
between p98 and d90 as the modulation width. The distal margin, also called the distal dose 
falloff (DDF), is defined by the distance between d20 and d80 [9]. A compromise between a 
flat dose profile and a sharp DDF typically has to be made, as a sharper DDF can be achieved 
by increasing the weight of the distal peak and reducing the weight of the second peak. This 
would, however, lead to hot and cold spots in the dose distribution. Similarly, an improvement 
in the flatness of the dose distribution would also increase the DDF shoulder [35]. An example 
of a lateral dose distribution is shown in Figure 3.10.  
 
Figure 3.10: Illustration of a lateral dose distribution. Taken from [9]. 
The field size is defined at the 50% level, while the lateral penumbra can be specified by both 
20%-80% and 50%-95%. The former is commonly used when describing the general quality 
of the penumbra, while the latter is needed for determining the margins of an aperture in the 
PS modality [9].  
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3.5 The Treatment Room 
The treatment room consists of the gantry and the patient treatment table. The patient is placed 
on the table, with great care being put into reproducing the position they were in during 
imaging. One way to achieve this is through the use of wedges and accessories holding the 
patient in place. There are also techniques in place which minimizes the various errors 
associated with organ or respiratory motion [28].  
3.5.1 Patient Orientation 
The relative orientation of the patient and the beam is of great importance in particle therapy. 
Usually, the orientation of both the beam and the patient can be manipulated. This is done by 
rotating the gantry and the treatment table, which allows for a wide range of treatment angles.  
How the patient is orientated on the table will depend on the location of the target volume, as 
this might affect the angles of irradiation. The most common patient orientation is Head First 
– Supine (HFS), where the patient lies on their back, facing towards the ceiling. This, as well 
as other common orientations, are shown in Figure 3.11.  
 
Figure 3.11: Various patient positions in radiation therapy. Taken from [39]. 
33 
 
3.5.2 Coordinate Systems 
The coordinate systems associated with the patient and the treatment room are defined by the 
International Electrotechnical Commission (IEC). The fixed and gantry systems are both 
coordinate systems within the treatment room. As the name would suggest, the former system 
is fixed within the room. The gantry system, however, is a daughter system of the fixed, and 
may rotate relative to it. Both systems share a common y-axis, pointing toward the virtual 
gantry bearing, around which the gantry system rotates. The z-axis of the fixed system points 
upward, and the x-axis is perpendicular to them both. When the gantry angle is equal to zero, 
the two systems overlap[39]. The treatment room systems are illustrated in Figure 3.12. 
 
Figure 3.12: The fixed and gantry coordinate systems. Taken from [39]. 
The patient coordinate system is defined as having the positive x-axis toward the left arm of 
the patient, the positive y-axis toward the head and the positive z-axis pointing up out of the 
chest of the patient. This means the coordinate system will depend on the orientation of the 
patient. For an HFS patient, the patient coordinate system overlaps with the fixed system of 




Figure 3.13: The patient coordinate system. Taken from [40]. 
3.6 DICOM 
Particle therapy has a lot of steps, from imaging to delineation to planning to treatment, which 
need to be able to move information between them. The standard format for storing medical 
imaging information and data in medicine is the Digital Imaging and Communications in 
Medicine (DICOM) file format [39]. Such files allow for the storing of images, along with 
relevant information about the patient in question. There are different types of DICOM, some 
of which are being used to store information about structures delineated by a physician, while 
others can be used to store treatment plans. DICOM files can be an absolute necessity when 
setting up a simulation environment. 
DICOM files use the DICOM standard coordinate system. This coordinate system is patient-
based, with the positive x-axis defined as pointing toward the left arm, the positive y-axis 
pointing out of the back of the patient, and the positive z-axis pointing up through the head. 
Correctly transforming between this coordinate system and those explained in the previous 
section is of great importance when setting up a simulation.  
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DICOM files group information into data sets, similar to dictionaries in Python. A DICOM 
file consists of elements, such as the name of the patient or the energy of the beam, which are 
paired together with a unique tag. These tags are used to retrieve the DICOM elements.   
The different types of DICOM files are identified by their unique ID tag. The scanned images 
of the patient are stored in RT Image files, with each file corresponding to a slice from the CT 
scan. Examples of what each file contains include information about the patient position and 
orientation, the dimensions of the image, as well as density information about the patient. The 
latter is retrieved from a two-dimensional array containing the various HU values of the image. 
While these types of DICOMs contain the actual images of the patient, the structures 
delineated by a physician are stored in a different type of DICOM.  
The RT Structure Set is a type of DICOM in which the information about the various ROIs is 
stored. This includes the coordinates and borders of the various organs, the GTVs, CTVs and 
PTVs, as well as the body itself. These files are necessary when creating DVHs, in addition to 
being useful when plotting and evaluating the dose distribution. Only one such file is needed 
per patient.  
The RT Dose files contain the dosimetric information. This includes the dose distribution as 
calculated by the TPS, with all relevant details. One RT Dose file is made for each field, 
although these can be combined into one file. The dose information is stored similarly to how 
the image files stores density information, except for being three-dimensional. The dose files 
also contain information about the scoring region and grid size. These DICOMs are useful for 
comparing delivered or recalculated dose distributions with those of the TPS.  
The RT Plan file contains information about the treatment plan itself, as defined by the TPS. 
Only one file is needed per treatment plan, and it is from this file essential data needed for the 
beamline setup is retrieved. This includes information about the particle beam, the angles of 
the gantry and treatment table, the various fields used, isocenter of the target volume, and 




3.7 Monte Carlo 
Monte Carlo (MC) simulations are the most accurate methods of simulating particle 
interactions due to the way the underlying physics are modeled. In an MC simulation, the 
interactions of particles can be simulated on a particle-to-particle basis. MC makes use of 
theoretical models and parametrization, as well as experimental data for electromagnetic and 
nuclear interactions. The knowledge of the trajectory, interactions and energy deposition of 
one particle, including potential secondaries, is called the particle’s history. The particles are 
simulated in a well-defined geometry, step-by-step, using cross-section data, which gives the 
probability of a given interaction, and sampling from a random number generator. The size of 
the steps between which the particles are measured should be small, as this minimizes the 
difference in the size of cross-sections at the beginning and the end of a step. Choosing a 
smaller step size does, however, increase the computation time [12].  
Due to the stochastic nature of the processes involved, a great number of particles need to be 
simulated in order to minimize the uncertainty of the results. Uncertainty in MC depends on 
the amount of histories tracked (N), with the error being proportional to 1/√N. Increasing the 
number of histories will also increase the amount of computation time needed, which makes 
MC inefficient for use in the clinic [12].  
Several different types of MC codes are used in proton therapy, such as Geant4 [41, 42], 
TOPAS [43] and FLUKA [14, 15] – the latter of which was used in this project. Setting up an 
MC simulation requires the entire environment to be defined, which includes the particles that 
are to be tracked, the entire tracking geometry, the physical processes governing the various 
interactions, the manner in which the particles are to be tracked and how the simulated data is 
to be handled and recorded. Setting up an MC simulation requires information about the 
particle beam and the geometry and composition of the treatment nozzle, as well as clinical 
information about the patient [12].  
3.8 FLUKA 
FLUKA is a highly accurate, general-purpose tool used for calculating how particles propagate 
and interact with matter. It can simulate about 60 different types of particles from 1 keV up to 
37 
 
several TeV, and even higher for certain particles. It supports complex geometries and comes 
with its own graphical user interface, called Flair [44]. While FLUKA requires little 
programming knowledge for most tasks, the user does need to create an input file in order to 
run a simulation. While such files can be made directly in Flair, it is not unusual to create them 
beforehand, for example using a script, and later importing them into Flair [14].  
The information needed for the input file depends on the type of simulation desired. The input 
files themselves are ASCII text files consisting of a sequence of option lines (“cards”), which 
all follow the same structure by default. These cards contain information such as 
documentation in the form of comments and titles, beam characteristics, geometry and 
material definitions, which quantities are to be scored and how many histories are to be run.  
Although there are strict rules as to the alignment and amount of characters allowed in a card, 
increased flexibility can be achieved as Flair comes bundled with a preprocessor. This makes 
it possible to add conditionals and parametric expressions to the input file. Cards which include 
such expressions do, however, still need to follow the FLUKA input format [14].  
3.9 The IBA Universal Nozzle  
The PS patients whose treatment plans were recalculated in this project were originally treated 
with the IBA Universal Nozzle system, so named as it allows for a variety of treatment 
modalities. The double-scattering mode of the system was used for treating the PS patients in 
this project. The first upstream component in the nozzle is an ionization chamber for 
monitoring the beam properties, followed by the first scatterer, which consists of a 
configuration of up to eight scattering foils made of lead or aluminium. These foils, which 
vary in thickness, are inserted independently depending on the required scattering 
compensation. The thickness of the first scatterer is chosen so as to reduce the change of 
scattering power in the downstream range modulator and second scatterer, which varies 
depending on the beam energy. Range modulation in the IBA nozzle is achieved using one of 
three RM wheels, each of which consists of three range modulator tracks, in conjunction with 
BCM. The steps of the RM wheels are scatter compensated in order to decrease the change in 
scattering power associated with a varying beam energy. Downstream of the RM wheel, using 
one of three contoured scatterers, the particle beam is spread out into a uniform field with a 
38 
 
diameter of up to 24 cm. Depending on the specific scatterer used, beam ranges from 4.6 to 
28.4 g/cm2 in water can be achieved. The scatterers are made from lead and Lexan, with the 
latter being added for energy compensation [35]. The range span is divided into eight options, 
each of which consists of a particular combination of first and second scatterers, as well as a 
specific RM wheel track. Each of these options are further divided into suboptions, for which 
a particular BCM is custom designed [29]. Downstream of the contoured scatterer a variable 
collimator blocks parts of the beam from entering the subsequent beamline components, 
followed by a second ionization chamber used for beam monitoring. Beyond this point, one 
of three retractable snouts are mounted, in which the aperture and compensator is located. The 
snout, the choice of which depends on the required field size, collimates the beam outside of 






The aim of this project was to simulate the two main treatment modalities in proton therapy, 
and see whether or not a variable RBE, which takes LETd into account, will affect the 
dosimetric benefits of PBS over PS. In addition to comparing the two modalities to one 
another, it was also desirable to compare the dose distributions calculated by the Eclipse TPS 
and the MC code FLUKA [14, 15] (v2011.2x). This was done using anonymized treatment 
plans made for patients previously treated with PS, as well as newly created PBS treatment 
plans for the same patients. The PS patients were originally treated with the IBA Universal 
Nozzle at the University of Florida. While an inhouse script could be used to set up the PBS 
simulation environment, a script for the automated creation of PS input files in FLUKA had 
to be created by the author of this thesis. This was done using the Python (v2.7) programming 
language along with the Pydicom (v0.9.9) library. The manner in which the script uses data 
extracted from the DICOMs of a given patient to define the specific simulation is described in 
this chapter.  
Once run, the results of the FLUKA simulations were extracted and converted to DICOMs 
using an inhouse script for the conversion. Results for both a constant and a variable RBE 
were obtained for both modalities. The dosimetric indices and dose distributions could then 
be compared, not only between the two modalities, but also between the TPS and FLUKA.   
Dose distributions were recalculated for 3 pediatric posterior fossa tumor patients previously 
treated with PS. Due to the increased healthy tissue sparing provided by proton therapy 
compared to photon therapy, the former modality has been increasingly used to treat brain 
tumors in children. While this has been suggested to lead to a lower rate of both physical and 
cognitive secondary malignancies, brainstem necrosis has been reported as a potential 
consequence of using proton therapy to treat brain tumors [45]. All patients in this project 
were prescribed a dose of 54 Gy, as well as dose constraints of D50 < 54 Gy and D1CC < 56.1 
Gy for the brainstem and brainstem core, respectively. All patients were treated using three 
treatment fields. The dose distributions were obtained using a fixed RBE of 1.1, as well as a 
variable RBE calculated using the McNamara model. LETd- and variable RBE-distributions 
were also calculated, with the former being used to calculate the latter. Additionally, the 
recalculated dose distributions were compared with those calculated by the Eclipse TPS. As 
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can be seen from equation 2.10, the a- and b-values for both the reference radiation and the 
proton beam is required in order to obtain the variable RBE. The ax /bx-ratio used was 2 Gy, 
as this represents the late responding tissue found in the central nervous system [46]. This ratio 
was chosen as the dose delivered to various OARs, specifically the brainstem and the 
brainstem core, was of interest in this project. The a/b-values for the proton beam were found 
through equations 2.11 and 2.12, with the LETd-values being those calculated by FLUKA. 
4.1 Setting Up the Simulation 
4.1.1 Standard Input File and Settings 
The following is included in a standard input file, according to the FLUKA manual [14]: 
• Title and comments for documentation purposes 
• Definition of the problem geometry 
• Definition of the materials and material assignments 
• Definition of the particle source 
• Definition of requested scoring quantity and method 
• Definition of biasing schemes 
• Definition of problem settings such as step size, energy cutoffs or physical settings not 
simulated by default.  
• Initialization of the random number sequence 
• Starting signal and number of requested histories.  
 
FLUKA has several default physics settings, which can be accessed using the DEFAULTS 
card, which are suitable for various kinds of problems. The HADROTHErapy DEFAULTS 
card was used in this project, as it is optimized for hadron therapy. 
The settings for this card are also outlined in the FLUKA manual, and include: 
• Transport of electrons, positrons and photons is activated 




• Low-energy (including thermal) neutron transport is activated 
• Fully analogue absorption for low-energy neutrons 
• Particle transport threshold set at 100 keV, except for neutrons (1 × 10−5 eV) 
• Multiple scattering threshold at minimum allowed energy, for both primary and 
secondary charged particles 
• Delta ray production on with threshold 100 keV 
• Restricted ionization fluctuations on, for both hadrons/muons and EM particles 
• Tabulation ratio for hadron/muon dp/dx set at 1.03, fraction of the kinetic energy to 
be lost in a step set at 0.02 
 
4.1.2 Importing the Patient 
The patient geometry must be included in the simulation. In FLUKA, a convenient way to 
describe complex geometries is in terms of voxels, i.e. three-dimensional grids consisting of 
small, identical parallelepipeds. Each voxel contains density and material information, 
together forming a complete picture of the larger geometry. The voxels describing the patient 
geometry is stored in a voxel file (.vxl), which can be created in Flair. The CT DICOMs can 
be imported directly into Flair, and the HU numbers of the images can then be translated into 
material/density information using an algorithm defined by the user. An inhouse algorithm 
was used for this purpose in this project. Once created, the voxel file can be included in the 
VOXEL card of the input file, which also allows for the translation of the patient.  
It was desirable to place the isocenter of the target volume at the origin of the FLUKA 
coordinate system. The origin of the DICOM coordinate system depends on the scanner used, 
meaning the origin and isocenter does not necessarily overlap, as was the case in this project.  
The Image DICOMs contain the coordinates of the upper left-hand corner of the images 
(stored under the “Image Position” tag), while the Plan DICOMs contains the coordinates of 
the target isocenter (“Isocenter Position”). Using these values, the isocenter can be moved 
towards the origin. It will, however, still be a bit off. In FLUKA, coordinates mark the corners 
of the voxels, while in the DICOM system, coordinates mark the center of the voxels. This 
would result in an isocenter offset of half a voxel. The Image files contain the spacing between 
the voxels in the xy-plane (“Pixel Spacing”), as well as in the z-direction (“Slice Thickness”). 
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From these values, a correct translation of the patient was achieved using the following 
equations [40]: 
𝑥@E$-B =















Where the subscript “trans” refers to the translation, “image” refers to the image position, 
“iso” refers to the isocenter position, “pixel” refers to the pixel spacing, and “slice” refers to 
the slice thickness. The division by 10 is due to the fact that FLUKAs standard unit of distance 
is centimeter, whereas DICOM uses millimeter.  
4.1.3 The Particle Beam 
The particle beam energy is located in the Plan DICOMs, specifically under the “Nominal 
Beam Energy” tag. The BEAM card holds information about the particle beam itself, such as 
the energy, the type of radiation (here “proton”), as well as the divergence of the beam in the 
x-, y- and z-direction. Before being added, the energy had to be transformed from MeV to 
GeV, as the former is the DICOM standard while the latter is the FLUKA standard. 
Additionally, for PS, the beam energy had to be calibrated somewhat, with a correction factor 
that depended on the IBA nozzle option chosen. The correction factor, found inhouse, was 
necessary because of an offset in the pristine Bragg peaks calculated by the TPS and FLUKA.  
In the case of PBS, where the beam energy changes during treatment, a variety of beam 
energies are present, corresponding to the different spot positions used during treatment. These 
were extracted and added to the user-defined routine described in the next section. The 
maximum beam energy was, however, added to the BEAM card, as is recommended by the 
FLUKA manual.  
43 
 
For PS, a BEAMPOSit card was added below the BEAM card. This card defines the 
coordinates of the center of the beam spot, as well as its direction. The center was placed at 
the origin of the XY-plane, but far down the negative z-axis with the direction pointing in the 
positive z-direction. This places the beam upstream of all beamline geometry. The handling 
of the PBS beam direction is explained in section 4.1.5.  
4.1.4 Source Routine 
Complicated simulation environments, such as the ones described in this project, requires user-
defined routines. Such routines are included in FLUKA by adding a SOURCE card. This card 
tells FLUKA that it is to use a user-defined source routine to sample the primary particles.  
The source routine is written based on certain patient and treatment specific parameters, 
making them different for the two modalities. In the case of PS, creation of the source file 
requires information about the RM wheel used, as well as the BCM, both of which change 
during treatment. Both of these values can be obtained from the Plan DICOMs, found under 
the “Range Modulator ID” and the “Beam Current Modulation ID” tags, respectively. The 
latter does not give the BCM value directly, however, but rather a specific nozzle option, from 
which the required BCM could be obtained.  
For PBS, the source file had to include information about the patient position and the energies 
used, the location of which is explained above, as well as the angle of irradiation, i.e. the gantry 
angle. Additionally, several parameters which describe the beam spots used in scanning were 
needed, all of which were obtained from the Plan DICOMs. The required beam spot 
parameters are described below: 
-  The x- and y-coordinates of the scanning spots, as projected onto the machine 
isocentric plane in the IEC Gantry system. The scan spot positions are found under the 
“Scan Spot Position Map” tag. 
- A set of meterset weights corresponding to scan spot positions. The order of the 
weights matches the positions of the scanning spot positions. These weights are found 
under the “Scan Spot Meterset Weights” tag. 
- The scanning spot size, specified by a numeric pair, as calculated using the Full Width 
Half Maximum (FWHM). The spot size is measured in air in the x- and y-direction at 
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the isocenter of the IEC Gantry system.  This parameter is stored under the “Scanning 
Spot Size” tag.  
In this project, inhouse source files, written in Fortran 77, were used for this purpose, after 
first being modified according to the chosen treatment modality and its specific parameters.  
4.1.5 The Beam Direction 
In radiation therapy, the various angles of irradiation are achieved by rotating the gantry 
system around the treatment table, which can also be rotated. Additionally, the orientation of 
the patient can be changed. The gantry angle is found in the Plan DICOMs under the 
“GantryAngle” tag. The three different parameters which describe the angles of the treatment 
turntable can also be obtained from this DICOM. These three angles, which make up the 
patient support coordinate system, are the patient support angle (stored under the “Patient 
Support Angle” tag), the tabletop pitch angle (“Table Top Pitch Angle”) and the tabletop roll 
angle (“Table Top Roll Angle”). The patient support angle was the only one of these relevant 
for this project and it describes the table rotation about the z-axis in the IEC Fixed coordinate 
system. This is illustrated in Figure 4.1.  
 
Figure 4.1: The patient support coordinate system. Taken from [39]. 
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Simulating the angles of irradiation was handled differently for the two modalities. As 
mentioned in section 4.1.3, a BEAMPOS card was not used to define the origin or direction 
for the PBS modality. Instead, this was done by changing parameters within the SOURCE 
routine, specifically the TXFLK and TYFLK parameters[40]. These describe the direction 
cosines of the beam with respect to the x- and y-axis in the FLUKA coordinate system, 
respectively, and can be calculated using simple trigonometry and the necessary angles 
obtained from the DICOMs.   
For PS, on the other hand, the beamline was kept stationary with the patient being rotated. 
This was done by extracting the gantry and patient angles and adding them to ROT-DEFIni 
cards. Such cards define the rotations and translations that are to be applied to geometry or 
binnings (see section 4.1.7). The ROT-DEFI cards needs to be assigned an axis of rotation, 
the translation in the x-, y- and z-directions (if so desired), as well as the polar and azimuthal 
angles of rotation. Complex transformations can be split up into several consecutive cards for 
simplicity.  Before the patient could be rotated relative to the beamline, they had to be correctly 
aligned within the FLUKA coordinate system. With the target volume already placed at the 
isocenter, this was achieved with a ROT-DEFI card with an azimuthal and polar rotation of 
180º and 270º, respectively. Both rotations were done with respect to the FLUKA x-axis, 
placing the patient in the HFS position relative to the beamline. Once this was achieved, the 
patient support and gantry angles were added as polar rotations with respect to the FLUKA z- 
and y-axis, respectively. 
4.1.6 Geometry 
The PBS beam does not move through any beam shaping elements. Instead, magnets are used 
to scan the beam across the target, with the energy of the beam being adjusted as required. As 
explained above, the SOURCE routine handles this during the simulation, changing the beam 
energy and direction as required. The steering magnets were therefore not included in the 
simulation environment, and the only geometric figure present for this modality was therefore 
the patient.  
PS, on the other hand, required the entire beamline to be defined. In FLUKA, complex 
geometries can be created from simple geometric figures which must be assigned a specific 
material. The non-patient specific beamline components (i.e. everything except the aperture 
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and compensator) could be defined in their own files, provided they follow the FLUKA input 
format. The components required for the simulation could then be imported by the input file 
using the #include-directive in Flair. Inhouse geometric definitions based on the IBA Nozzle 
blueprints were used in this project. While some geometric structures were the same for all 
patient setups (i.e. the ionization chambers and a field mirror used for beam monitoring), some 
depended on patient specific information stored in the Plan DICOMs. The components that 
could be directly obtained from these were the RM wheel (“Range Modulator ID”), the snout 
(“Snout ID”) and the second scatterer, which is stored under the “Lateral Spreading Device 
ID” tag. For range modulation, knowing which RM wheel is used is not enough. As explained 
in chapter 3, the entire wheel is not necessarily to be irradiated, depending on the desired 
modulation width. The stop angle of a given field, i.e. the angle beyond which the wheel is not 
to be irradiated, depends on both the modulation width and the nozzle option. The various stop 
angles were obtained using the following equations:  
𝑆𝐴I = 𝑎5 +𝑀𝑎I +𝑀!𝑎! +𝑀J𝑎J +𝑀7𝑎7 
𝑆𝐴! = min(𝑖𝑛𝑡(𝑆𝐴I ∗ 0.71111 + 0.5), 255) (4.2) 
𝑆𝐴 = 𝑆𝐴!/0.71111 
where a0-a4 are option dependent coefficients, M is the modulation width, min() returns the 
lowest of the values contained within its parentheses and int() returns the numeric value within 
its parentheses as an integer. The tag under which the second scatterer is found is actually a 
daughter tag of the “Lateral Spreading Device Sequence” tag. This tag is split into several 
elements, each of which correspond to a specific scattering device. In this project, only the 
name of the second scatterer was stored in the DICOMs, meaning the first scatterer 
configuration had to be found another way. The theoretical thickness of the first scatterer was 
obtained using the following equation:  
𝐹𝑆' = 𝑎5 + 𝑎I𝑅 + 𝑎!𝑅 (4.3) 
where a0-a2 are option dependent coefficients and R is the range of the proton beam. Once the 




Which variable collimator to be used is obtained indirectly from the Plan DICOMs, as it solely 
depends on the nozzle option. The aperture and the compensator had to be created for each 
individual treatment field. Information about both the aperture and the compensator is 
contained within the Plan DICOMs, specifically under the “Ion Block Sequence” and the “Ion 
Range Compensator Sequence” tags, respectively. A slightly modified inhouse script using 
the information stored under these tags, as well as the “Snout ID”, was used to generate these 
structures.    
4.1.7 Scoring 
The scoring in FLUKA was done using USRBIN cards, which allow for the scoring of several 
different quantities using a binning detector. A binning is a regular spatial mesh, independent 
from the problem geometry and defined by the user. In addition to defining the dimensions of 
the scoring grid, the USRBIN card defines the type of particles which are to be tracked and 
which logical output unit is to be used. In order to make comparisons between the dose 
calculations, the dose should be scored over the same region for not only the two modalities, 
but also for the TPS and MC. The parameters describing the TPS grid are all found in the Dose 
DICOMs. Using these parameters, along with the Isocenter Position obtained from the Plan 
DICOMs, a scoring grid in FLUKA could be defined. The necessary Dose parameters are 
listed below: 
- The x-, y- and z-coordinates of the upper left-hand corner (center of the first voxel 
transmitted) of the image, in mm. These coordinates are stored under the “Image 
Position (Patient)” tag. 
- The physical distance in the patient between the center of each pixel in mm, specified 
by a numeric pair. Stored under the “Pixel Spacing” tag.  
- The nominal slice thickness in mm. Stored under the “Slice Thickness” tag.  
- The number of bins in the x-, y- and z-direction. Stored under the “Columns”, “Rows” 
and “Number of Frames” tags, respectively. 
Using these parameters, the scoring grid can in be defined through equations (4.4) [40]: 
𝑥#A- =

















𝑥#$% = 𝑥#A- +
𝑥KA-B × 𝑥>A%",
10  
𝑦#$% = 𝑦#A- +
𝑦KA-B × 𝑦>A%",
10  
𝑧#$% = 𝑧#A- +
𝑧KA-B × 𝑧B,AH"
10  
Where the subscript “image” refers to the image position, “pixel” refers to the pixel spacing, 
“slice” refers to the slice thickness and “bins” refers to the number of bins in the given 
direction. The division by 10 is again due to the fact that DICOM and FLUKA use different 
units for distance, while the pixel spacing/slice thickness division by 2 is because they refer to 
different parts of the voxel.  
While the scoring grid now is both correctly placed and defined for the PBS modality, this is 
not the case for PS. This is due to the fact that when simulating PS, the patient is rotated instead 
of the beamline geometry. By adding ROT-DEFI cards with the same exact rotation as that 
used on the patient, the scoring grid gets placed correctly. The rotation is assigned to the 
scoring grids using a ROTPRBIN card.  
Although the above description makes it possible to place the scoring grid correctly, it is 
important to make sure the quantities scored are the same as well, at least if one is to make 
comparisons between the TPS and FLUKA. While FLUKA allows for the scoring of dose to 
specific materials, a TPS generally does not. Instead, the algorithms used in such systems tend 
to score the dose to water. While the ability to score dose over heterogeneous tissue is a 
strength of MC codes, it makes comparing the two systems more difficult. In FLUKA, the 
scoring of dose to water can be achieved by adding a user-defined routine, which can be stored 
in a fluscw.f file. Such routines can be used for weighting particle fluences in a particular 
medium, from which the dose to water can be calculated. The dose to water is found by 
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multiplying the measured fluence of charged particles in the medium with the LET in water. 





where Dw is the dose to water, Fm is the charged particle fluence in the given medium, LETw 
is the linear energy transfer in water and rw is the water density. External routines, such as 
fluscw.f, can be added to FLUKA using the USERWEIG card. Several scoring routines can 
be added to a single fluscw.f file. Which specific routine is chosen for a given USRBIN card 
will depend on its output unit, which is assigned to the card by the user. Several USRBIN 
cards can therefore be included in a single simulation. A fluscw.f file developed inhouse was 
used in this project. 
4.1.8 Random Seed and Starting 
Before the simulation could be run, a random seed had to be added to the input file. Such 
seeds, which are placed in a RANDOMIZe card, initialize different and independent random 
sequences for each input file. The seeds were obtained from the Random module in Python. 
Making the simulation run requires a START card, which also contains the number of primary 
histories which are to be simulated. The START card is mandatory and placed at the end of 
the input file.  
4.2 Generating the Results 
4.2.1 Scoring Cards 
Using the methods described above, a simulation environment for both proton therapy 
modalities were defined. The simulations were run using 300 million particles per field, and 
each treatment plan was optimized using SFUD. The fixed- and variable RBE dose 
distributions of both modalities were scored, as well as the LETd distributions. This was 
achieved by adding three USRBIN cards to the input files. The scored quantities are listed 
below:  
• Unit 50: The dose to water deposited by all particles 
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• Unit 40: The dose to water deposited only by protons 
• Unit 41: The dose to water deposited by protons, multiplied with the electronic 
stopping power of the protons, i.e. the unrestricted LET.  
With the chosen output units corresponding to specific scoring routines in the fluscw.f file. 
From these quantities, the LETd distribution could be calculated offline using equation (2.8), 
with unit 41 as the numerator and unit 40 as the denominator. The LETd could then be further 
used to calculate the variable RBE weighted dose distribution using the McNamara model.  
4.2.2 Data Handling 
After the simulations had finished, and the desired quantities had been calculated, the 
distributions were exported into DICOMs using an inhouse script. Any dose deposited outside 
of the patient was removed, as the DICOMs generated by the TPS excludes this as well.  
Once the results had been extracted, various dosimetric indices of interest were obtained. This 
was done using the 3D Slicer software (v4.6.2), which is an open-source software platform 
used for visualization and medical image computing [47-49]. In addition to dosimetric 
information, the values needed for creating DVHs could also be obtained from Slicer. DVHs 
were then made using a slightly modified inhouse script, a script which also allows for the 
plotting and side-by-side comparison of dose distributions found in Dose DICOMs. The dose 
distributions found using the Eclipse TPS and FLUKA were all plotted for both PS and PBS, 
in addition to the LETd and the RBE distributions of each treatment modality.  
The mean and maximum doses delivered to the PTV, the brainstem and the brainstem core 
were obtained through Slicer. The D05 and D95 values of the PTV were also obtained, as 
these can be used to assess the dose conformity of a given treatment modality. Additionally, 
the D50 values of the brainstem and the D1CC value of the brainstem core were obtained in 




While the primary aim of this project was to compare the biological dose delivered by the two 
main proton therapy modalities, achieving this required the creation of a script which sets up 
the simulation. This was done in conjunction with a larger project in which the aim was to 
develop a Monte Carlo model of the IBA Universal Nozzle system in FLUKA, which would 
allow for the recalculation of PS treatment plans. 
The results presented in this chapter consists of figures illustrating calculated dose 
distributions, DVHs showing the dose delivered to various structures of interest as well as 
dosimetric parameters describing the dose delivery. Three structures are present in each dose 
plot presented in this chapter, which are the PTV, the brainstem and the brainstem core. 
Throughout the chapter, “TPS” refers to the Eclipse TPS, “RBE1.1” refers to the FLUKA 
calculated dose using a fixed RBE of 1.1 and “McNamara” refers to doses calculated using a 
variable RBE obtained from the McNamara model.  
5.1 Comparison of the Dose Estimates by Eclipse and 
FLUKA 
5.1.1 Passive Scattering 
Figure 5.1 shows the TPS (left) and RBE1.1 (middle) dose distributions delivered by PS to 




Figure 5.1: PS dose distributions calculated using the Eclipse TPS (left) and FLUKA RBE1.1 
(middle) for two single fields, as well as the combined distributions of all three treatment fields. The 
difference distributions are shown on the right. The PTV is marked with green, the brainstem with 
red and the brainstem core with orange. 
As the figure shows, the differently calculated dose distributions exhibit similar conformity 
around the target volume, although the difference plots show that there are some differences 
in dose deposition along the fields. Proximally and within the PTV, the TPS doses are either 
similar or slightly greater than those calculated by FLUKA. At the distal ends of the fields, 
however, the doses calculated by FLUKA exceed those calculated by the TPS. As both Figure 
5.1c and 5.1i show, a greater dose is calculated within both OARs by FLUKA. The differences 
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in the dose distributions could indicate the presence of heterogeneous tissue, which would lead 
to deviations in the particle ranges between the two dose calculation techniques. The TPS and 
FLUKA RBE1.1 calculated PS doses received by the different structures in patient 2 are shown 
in the DVH in Figure 5.2. 
 
Figure 5.2: Comparison of the PS doses received by the different structures in patient 2 as calculated 
by the Eclipse TPS (dashed lines) and RBE1.1 (solid lines).  
As the figure shows, the dose received by the PTV is very similar for the two dose calculation 
techniques. As is to be expected from Figure 5.1, the FLUKA curves describing the OARs 
deviate more than their TPS counterparts. While these curves converge for the doses received 
by less than 20% of the volumes, the FLUKA curves generally demonstrate a more gradual 
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decline, although these become steeper as the curves approach one another. The mean and 
maximum doses delivered to all structures of all patients by PS are shown in Figure 5.3. 
 
Figure 5.3: The mean and maximum PS doses delivered to the different ROIs calculated using TPS 
and RBE1.1. 
The mean doses delivered to the PTV are similar for the two dose calculation techniques, as 
is to be expected from Figure 5.2. The FLUKA mean dose is slightly greater than the TPS 
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dose for patient 1, with the opposite being true for patient 2 and 3. The mean doses calculated 
by the two techniques are, however, in all cases within 0.5 Gy of each other. The mean doses 
delivered to the OARs by FLUKA are in all cases greater than the doses delivered by the TPS, 
although the doses seem similar. The deviation in mean dose to the OARs is greater for patient 
2 than for the other patients. The maximum doses calculated by FLUKA are for all patients 
and structures greater than the doses calculated by the TPS. This deviation is still small, 
however, and never exceeds 1 Gy.  
5.1.2 Pencil Beam Scanning 
Figure 5.4 shows the TPS (left) and RBE1.1 (middle) dose distributions delivered by PBS to 




Figure 5.4: PBS dose distributions calculated using the Eclipse TPS (left) and RBE1.1 (middle) for 
two single fields, as well as the combined distributions of all three treatment fields. The difference 
distributions are shown on the right. The PTV is marked with green, the brainstem with red and the 
brainstem core with orange. 
As was the case for PS, the differently calculated dose distributions exhibit a similar 
conformity around the target volume. The difference plots once more demonstrate a similar or 
greater proximal dose deposition by the TPS, which is also the case inside the target volume. 
Distally, however, the differences are smaller for this modality. While the difference plot in 
Figure 5.4f have similar distal dose depositions, an increase in dose delivered by FLUKA is 
observed distally in Figure 5.4c and 5.4i, a region in which both OARs are located. As with 
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PS, the differences in the dose distributions is indicative of heterogeneous tissue, affecting the 
range calculations of the respective dose calculations. The TPS and FLUKA RBE1.1 
calculated PBS doses received by the different structures in patient 2 are shown in the DVH 
in Figure 5.5. 
 
Figure 5.5: Comparison of the PBS doses received by the different structures in patient 2 as 
calculated by the Eclipse TPS (dashed lines) and RBE1.1 (solid lines). 
As the figure shows, the dose coverage of all structures is quite similar for the two techniques. 
The TPS curve which describes the PTV is slightly greater than its FLUKA counterpart, 
mainly above doses received by 80% of the volume, below which the curves start to converge. 
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The curves which describe the OARs, on the other hand, are very similar down to the doses 
received by 60% of the volume, at which point the TPS curves overtake the FLUKA curves. 
The resulting divergence is not great, however, and the curves do start to approach their 
counterparts as the volume percentage decreases, even converging in the case of the brainstem. 
The mean and maximum doses delivered to all structures of all patients by PBS are shown in 
Figure 5.6. 
 




Both the mean and maximum doses delivered to the ROIs are very similar for the two 
techniques, with neither showing any significant divergence from the other. However, the TPS 
calculated mean doses delivered to the PTV are slightly greater than those calculated by 
FLUKA, which is to be expected from Figure 5.5. All dose deviations between the two 
techniques are below 1 Gy. 
5.2 Comparison of the FLUKA Dose Estimates 
5.2.1 Passive Scattering 
Figure 5.7 shows the FLUKA dose distributions delivered by PS to patient 2. The McNamara 
calculated doses are on the left and the fixed RBE1.1 calculated doses are in the middle. The 




Figure 5.7: PS dose distributions calculated using McNamara (left) and RBE1.1 (middle) for two 
single fields, as well as the combined distributions of all three treatment fields. The difference 
distributions are shown on the right. The PTV is marked with green, the brainstem with red and the 
brainstem core with orange. 
As the difference plots show, the doses calculated using McNamara are in all cases greater 
than those found using a fixed RBE of 1.1. While there is a proximal buildup of increased dose 
from McNamara, the greatest dose difference is at the distal sides of the target volume. The 
region of largest dose deposition contains within it both of the OARs. The McNamara and 
RBE1.1 calculated PS doses received by the different structures in patient 2 are shown in the 





Figure 5.8: Comparison of the PS doses received by the different structures in patient 2 calculated by 
RBE1.1 (dashed lines) and McNamara (solid lines). 
As the figure shows, there is a significant deviation between the two dose calculation 
techniques. While the curves describing a given structure are quite similar in appearance, the 
McNamara curves are in all cases greater than those associated with RBE1.1. The McNamara 
PTV curve appears to deviate in a scaled-up fashion from the RBE1.1 curve and the distance 
between them is quite constant across the PTV volume. The curves which describe the OARs 
deviate slightly more. While these curves approach the PTV curve in both cases, the 
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McNamara curves have a more gradual slope and they completely converge with the PTV 
curve for doses received by less than 40% of the volume. This indicates a greater relative dose 
being deposited to the OARs in the McNamara calculation. The mean and maximum FLUKA 
calculated PS doses are shown in Figure 5.9. 
 
Figure 5.9: The mean and maximum PS doses delivered to the different ROIs calculated using 
RBE1.1 and McNamara (MCN). 
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For all patients, the McNamara calculated doses exceed the RBE1.1 calculated doses. This is 
the case for both the mean and the maximum doses delivered to all structures of interest, which 
would indicate that the McNamara RBE values are greater than the fixed value of 1.1 within 
all of these. The deviation of the dose values is around 5-7 Gy for all structures and patients.  
5.2.2 Pencil Beam Scanning 
Figure 5.10 shows the FLUKA dose distributions delivered by PBS to patient 2. The 
McNamara calculated doses are on the left and the fixed RBE1.1 calculated doses are in the 





Figure 5.10: PBS dose distributions calculated using McNamara (left) and RBE1.1 (middle) for two 
single fields, as well as the combined distributions of all three treatment fields. The difference 
distributions are shown on the right. The PTV is marked with green, the brainstem with red and the 
brainstem core with orange. 
While there is an increased dose conformity compared to PS, the same tendencies are apparent 
in Figure 5.10 as those present in Figure 5.7. A greater dose deposition is once again found 
both within and at the distal ends of the target volume, leading to an increase in the dose 
delivered to the PTV as well as to the OARs. Additionally, the difference plots demonstrate a 
slight proximal buildup, although less significant than for PS. The McNamara and RBE1.1 
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calculated PBS doses received by the different structures in patient 2 are shown in the DVH 
in Figure 5.11. 
 
Figure 5.11: Comparison of the PBS doses received by the different structures in patient 2 as 
calculated by RBE1.1 (dashed lines) and McNamara (solid lines). 
As was the case in Figure 5.8, a significant deviation between the two dose calculation 
techniques is apparent in Figure 5.11. The curves which describe the doses calculated by 
McNamara are for all structures greater than those found by RBE1.1. All of the McNamara 
curves appear to deviate a relatively fixed amount from their RBE1.1 counterparts, something 
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which was not the case for PS. The mean and maximum FLUKA calculated PBS doses are 
shown in Figure 5.12. 
 
Figure 5.12: The mean and maximum PBS doses delivered to the different ROIs calculated using 
RBE1.1 and McNamara (MCN). 
As is to be expected from Figures 5.10 and 5.11, the McNamara calculated doses exceed the 
RBE1.1 calculated doses to all structures. This is the case for both the mean and the maximum 
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doses, which was the case for PS as well. The deviation between the two dose calculation 
techniques is around 5-7 for this modality as well.  
5.3 Comparison of PBS and PS Dose Estimates  
5.3.1 Doses Calculated with RBE1.1 
Figure 5.13 shows the RBE1.1 dose distributions delivered by PBS and PS to patient 2. The 
PBS doses are on the left and the PS calculated doses is in the middle. The dose difference 




Figure 5.13: PBS (left) and PS (middle) dose distributions calculated using RBE1.1 for two single 
fields, as well as the combined distributions of all three treatment fields. The difference distributions 
are shown on the right. The PTV is marked with green, the brainstem with red and the brainstem core 
with orange. 
The PBS exhibits a greater dose conformity than PS, as expected from theory and the 
previously presented results. The difference distributions show that the PS modality deposits 
a generally larger dose proximally than PBS does. However, this is also the case for the region 
immediately surrounding the target volume, a region in which both OARs are located. 
Although the difference plots show a greater distal dose deposition for the PBS modality, the 
dose deposited to the OARs by PS appear to be slightly greater than the dose deposited by 
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PBS. The doses deposited to the PTV is similar for the two modalities. The RBE1.1 doses 
received by the different structures in patient 2 are shown for both treatment modalities in the 
DVH in Figure 5.14. 
 
Figure 5.14: Comparison of the PS (dashed lines) and PBS (solid lines) doses received by the 
different structures in patient 2 calculated with RBE1.1. 
As the figure shows, PS is expected to deliver a greater dose to all structures. While the PTV 
curves are very similar, the deviation between the two modalities is most apparent when 
considering the curves which describe the OARs. For these structures, the PBS curves have a 
steeper slope, indicative of a smaller dose delivered to these structures. Although the brainstem 
curves eventually converge, this is not the case for the brainstem core. Based on Figure 5.14, 
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PBS demonstrates a similar target coverage as PS, but with a greater sparing of the OARs. The 
mean and maximum RBE1.1 calculated doses delivered by PS and PBS are presented in Figure 
5.15. 
 




The mean dose delivered to the PTV is quite similar for the two modalities, as is to be expected 
from Figure 5.14, with the PS doses being slightly greater than the PBS doses. The opposite 
is mainly true when considering the maximum doses to the PTV, with patient 3 being the 
exception. The mean doses delivered to the OARs are in all cases greater for the PS modality, 
which is also consistent with the results presented in Figures 5.13 and 5.14. The maximum 
values received by these structures are, however, comparable between the two modalities, 
although the PS maximums tend to be slightly greater.   
5.3.2 Doses Calculated with McNamara 
Figure 5.16 shows the McNamara dose distributions delivered by PBS and PS to patient 2. 
The PBS doses are on the left and the PS calculated doses is in the middle. The dose difference 




Figure 5.16: PBS (left) and PS (middle) dose distributions calculated using McNamara for two single 
fields, as well as the combined distributions of all three treatment fields. The difference distributions 
are shown on the right. The PTV is marked with green, the brainstem with red and the brainstem core 
with orange. 
Figure 5.16 exhibits the same tendencies present in Figure 5.13, with the PBS distribution 
demonstrating a superior dose conformity. With the exception of the distal ends of the fields, 
the difference plots show a greater dose being deposited by PS both proximally and 
immediately surrounding the target volume. Although the increased distal dose deposited by 
PBS partly affects the brainstem, the total dose delivered to the OARs appear to be generally 
higher for the PS modality. The dose deposited within the PTV appears to be generally greater 
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for PS. The McNamara doses received by the different structures in patient 2 are shown for 
both treatment modalities in the DVH in Figure 5.17. 
 
Figure 5.17: Comparison of the PS (dashed lines) and PBS (solid lines) doses received by the 
different structures in patient 2 calculated with McNamara. 
Although all the PS curves converge with the PBS PTV curve for doses received by 40% of 
the volume and below, the curves associated with the former modality predict a larger total 
dose delivered to all structures. The curves which describe a given structure in one modality 
deviate more from their counterparts than was the case in Figure 5.14, where a fixed RBE was 
considered. This indicates differences in the LETd of the two modalities, as this would lead to 
deviations in the delivered dose. Figure 5.17 predicts a greater mean dose deposited to the 
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PTV by PS than by PBS, although the latter demonstrates an increased sparing of the OARs. 
The mean and maximum McNamara doses delivered by both proton modalities are presented 
in Figure 5.18. 
 
Figure 5.18: The mean and maximum PS and PBS doses delivered to the different ROIs calculated 
using McNamara. 
As Figure 5.18 shows, PBS is expected to deliver a lower mean dose than PS to both of the 
OARs, which is consistent with Figure 5.16 and 5.17. The maximum doses delivered to the 
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brainstem cores are slightly greater for the PS modality, while the opposite is true for the 
brainstems. This is in good agreement with Figure 5.16. While the mean doses delivered to 
the PTVs are similar for similar for the two modalities, PBS is expected to deliver a greater 
maximum dose to this structure.  
5.3.3 Comparison of the PTV Dose Conformity 
Figure 5.19 shows a comparison of the D05-D95 values for both proton modalities for RBE1.1 
(left) and McNamara (right). 
 
Figure 5.19: D05-D95 values for PS and PBS calculated with RBE1.1 (left) and McNamara (right) 
As Figure 5.19 shows, the D05-D95 values of the PBS modality are in all cases greater than 
those of PS. This indicates a greater dose conformity for the former modality, which is 
consistent with Figures 5.13 and 5.16. While there is an increase for all patients when 
considering the PBS modality, this is not the case for PS, with the value even becoming lower 
in the case of patient 2. Additionally, the increase is more dramatic for PBS than for PS when 
comparing RBE1.1 and McNamara.  
5.3.4 Comparison of the Dose Constraints to the OARs 
A comparison of the D50 values of the brainstem calculated for both modalities using both 




Figure 5.20: Comparison of the PS and PBS D50 dose values of the brainstem, calculated with 
RBE1.1 (left) and McNamara (right) 
As the figure shows, the PS D50 values are in all cases greater than the PBS value. The 
differences between the two modalities is similar for both dose calculation techniques, 
although the McNamara values are greater than the RBE1.1 values. The McNamara values for 
patient 2 and 3 exceed the constraint of D50 < 54 Gy. The D1CC values of the brainstem core 
calculated for both modalities using both FLUKA dose calculation techniques are shown in 
Figure 5.21. 
 
Figure 5.21: Comparison of the PS and PBS D1CC dose values of the brainstem core, calculated with 
RBE1.1 (left) and McNamara (right) 
As was the case for the D50 values, the PS D1CC values exceed the PBS values for both dose 
calculation techniques. While all RBE1.1 values are below the constraint of D1CC < 56.1 Gy, 
the opposite is true for the McNamara dose values.  
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5.4 Comparisons of LETd and RBE  
5.4.1 Comparison of the LETd Distributions  
Figure 5.22 shows the LETd distributions of PBS (left) and PS (middle) delivered to patient 2. 
The difference between the distributions are shown in the right-hand panel. 
 
Figure 5.22: PBS (left) and PS (middle) LETd distributions for two single fields, as well as the 
combined distributions of all three treatment fields. The difference distributions are shown on the 
right. The PTV is marked with green, the brainstem with red and the brainstem core with orange. 
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As is expected from the increased distal doses in the difference plots in section 5.2, both 
modalities exhibit an increase in the LETd values at the distal ends of their respective fields. 
As the difference distribution in Figure 5.22i shows, the values are similar proximal to the 
target volume, as well as within the PTV. While PBS exhibits a greater LETd at the most distal 
parts of its fields in Figure 5.22i, Figure 5.22b indicates that PS has a greater LETd within the 
OARs. The LETd received by the different structures are for both modalities presented in the 
LETd volume histogram (LVH) in Figure 5.23.  
 
Figure 5.23: Comparison of the PS (dashed lines) and PBS (solid lines) LETd received by the 
different structures in patient 2. 
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The curves present in Figure 5.23 have very similar slopes when comparing the structures 
across the modalities. The PS curves are generally greater than the PBS curves for all 
structures, with the exception being the PBS brainstem curve. This curve, which has the 
longest tail of all the curves, overtakes its PS counterpart for LETd values inside 5% of the 
volume and below. The LETd within the target volume is lower than the LETd within the OARs 
for both modalities, which is consistent with the results presented in section 5.2. The mean 
and maximum LETd within each of the ROIs are presented in Figure 5.24 for both PS and 
PBS.  
 
Figure 5.24 The mean and maximum PS and PBS LETd values delivered to the different ROIs. 
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As Figure 5.24 shows, the mean LETd associated with each patient is similar for each structure 
when comparing the two modalities. While the PS mean LETd to the PTV exceeds that of PBS 
for patients 1 and 3, the opposite is true for the OARs and patient 2 and 3. Regardless, the 
deviations between the two modalities are small. When considering the maximum LETd, on 
the other hand, the PS values are generally greater than its PBS counterparts. The one 
exception is the max LETd delivered to the brainstem core of patient 2, although these are 
comparable in value.  
5.4.2 Comparison of the RBE Distributions 
Figure 5.25 shows the McNamara RBE distributions of PBS (left) and PS (middle) for patient 




Figure 5.25: PBS (left) and PS (middle) RBE distributions for two single fields, as well as the 
combined distributions of all three treatment fields. The difference distributions are shown on the 
right. The PTV is marked with green, the brainstem with red and the brainstem core with orange. 
The McNamara RBE distributions presented in Figure 5.25 are very similar to the LETd 
distributions in Figure 5.22. Both treatment modalities exhibit an increase in RBE at the ends 
of their respective fields, an increase which appears comparable when considering the 
difference plots in Figure 5.25. While the values are mostly comparable proximal to the target 
volume, PBS exhibits a greater value both within the target volume and at the distal ends of 
the fields. The RBE within the different structures for both treatment modalities are presented 




Figure 5.26: Comparison of the PS (dashed lines) and PBS (solid lines) RBE within the different 
structures in patient 2. 
As is to be expected from theory, Figure 5.26 is quite similar to the LVH presented in Figure 
5.23. Although the curves are generally closer together in Figure 5.26, the same tendencies 
occur in both. The curves which describe the OARs are greater than those describing the PTV, 
while the PS curves are generally greater than their PBS counterparts. However, while only 
the PBS brainstem curve overtook the PS curve in Figure 5.23, both PBS OAR curves overtake 
the PS OAR curves. The PBS curve which describes the brainstem core overtakes its PS 
counterpart for RBE values within 15% of the volume. Beyond this point the former curve has 
a more gradual slope, which leads to a slight tail. The PBS brainstem curve overtakes the 
corresponding PS curve for RBE values within 30% of the volume, beyond which point the 
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slope of the PBS curve flattens out, leading to a large tail. The mean and maximum RBE values 
within each structure is presented in Figure 5.27 for both PS and PBS.  
 
 




As Figure 5.27 shows, the mean RBE values within all structures are either comparable or 
greater for the PBS modality. The deviations between the two modalities are, however, quite 
small, indicating a comparable mean value delivered by both treatment modalities. The mean 
RBE within the OARs are either similar or greater than the mean RBE within the PTV for all 
patients, which is true for the maximum RBE values as well. The maximum values within the 
RBE are mainly greater for PBS than PS, with the exception being the RBE within the PTV 
of patient 2. Here, the RBE appears to be equal for the two modalities. The PBS maximums 
to the OARs exceed the PS maximums in all cases, most significantly so in the case of patient 





Using treatment information stored in various DICOM files, a PS proton therapy simulation 
could be defined with the required nozzle configuration. This made it possible to compare MC 
calculated dose distributions for the PS modality to the PBS modality. These could also be 
compared to their TPS calculated distributions.  
As was presented in the results (Figure 5.1 and 5.4) the dose distributions calculated with the 
TPS and RBE1.1 showed good agreement. For both proton treatment modalities, the FLUKA 
calculated dose distributions exhibited a similar dose conformity as those of the TPS. An 
increase in the distal dose deposition was observed in the FLUKA distributions of both 
modalities, although this was most significant for PS. This indicates the presence of 
heterogeneous tissue along the field path, which would cause discrepancies in the range 
calculations between the two dose calculation methods as this is not taken into account by the 
pencil-beam algorithms of the TPS. This agrees well with the findings made by Paganetti et 
al. [11]. A consequence of this would be the presence of a slightly greater TPS calculated dose 
more proximally within the fields, which is indeed what is observed in the both dose 
distributions. While the dose deposition within the PTV is similar for the two techniques, the 
increased distal dose deposition found by the RBE1.1 calculations would suggest an increased 
dose received by the OARs, in particular for the PS modality. The DVHs in Figure 5.2 and 5.4 
show that the two methods of dose calculation expect a similar dose to be received by the PTV 
for both treatment modalities. When considering the OARs, however, PS and PBS differ. 
While the FLUKA calculation for the latter modality estimates a slightly lower dose deposition 
within the OARs than the TPS does, the opposite is true for PS, which is consistent with their 
respective dose distributions. The mean doses delivered to the PTV are very similar for both 
techniques in either treatment modality, with all of them being within 2% of the prescribed 
dose of 54 Gy to this volume. For the PBS modality, the mean doses estimated by the TPS are 
in all cases slightly greater than their FLUKA counterparts, while no such tendency is apparent 
for PS. The opposite is true, however, when considering the mean doses delivered to the 
OARs. Although the mean PS doses are once again very similar, all the FLUKA estimates 
exceed the corresponding TPS doses, which is to be expected from the increased distal dose 
deposition observed in Figure 5.1. Such a tendency is not observed for the PBS modality. The 
maximum doses delivered to all structures are very similar for both techniques and both 
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modalities, although the PS RBE1.1 doses exceed the corresponding TPS doses for all patients. 
No such pattern occurs for PBS. The doses calculated with RBE1.1 and TPS are in all cases 
within 1 Gy of each other, i.e. below 2% of the prescription dose, which suggests that the 
distributions obtained from the two techniques are comparable.  
Comparisons between the FLUKA McNamara and FLUKA RBE1.1 dose distributions exhibit 
a significant difference between them for each treatment modality. While the McNamara doses 
exceed those of RBE1.1 everywhere, this is most noticeable within and on the distal sides of 
the target volume, where a region of increased dose deposition is apparent. This region, in 
which both OARs are contained, extends further for the PS modality compared to PBS. The 
regions of increased dose deposition in both figures correspond to the regions of increased 
LETd and RBE, which is consistent with the findings of Fjæra et al. [50] and Yepes et al. [23].  
The DVHs which compare the target coverages calculated by FLUKA McNamara and 
FLUKA RBE1.1 for both treatment modalities are consistent with their corresponding dose 
distributions. The two PTV curves appear to deviate in a constant manner for both modalities, 
which is also the case for the PBS curves which describe the OARs. For PS, on the other hand, 
the McNamara OAR curves have a more gradual initial slope than the RBE1.1 curves, 
indicating a greater relative dose delivered to these structures when a variable RBE is 
considered. The mean and maximum PS and PBS doses estimated by the two techniques 
deviate significantly for all patients. The level of deviation is similar for the two modalities, 
with all McNamara doses being 5-7 Gy greater than their corresponding RBE1.1 doses. This 
corresponds to an increase of up to 12% for all PTV doses and an increase of up to 17% for 
the mean OAR doses, while the maximum OAR doses deviate by about 13%. The size of the 
deviations suggests that the ROIs receive a non-trivial amount of excess dose when a variable 
RBE is considered, which is consistent with the findings of Giantsoudi et al. [25].  
The dose distributions in chapter 5.3 indicate that PBS provides a better dose conformity than 
PS, regardless of the dose calculation technique considered. The D05-D95 values show that 
this is indeed the case, with the differences between the two modalities being greater for the 
McNamara calculated doses. The dose distributions further indicate that PS delivers a greater 
proximal dose than PBS, while PBS deposits a greater distal dose at the very ends of the 
treatment fields. The PS doses immediately surrounding the PTV, however, are greater than 
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the PBS doses. The OARs are located at the intersection between the large distal doses 
deposited by both modalities, with PS appearing to deposit a greater dose than PBS to the 
brainstem core and vice versa for the brainstem. While the McNamara doses are greater than 
the RBE1.1 doses, the difference distributions are similar for both dose calculation techniques. 
The DVH which compares RBE1.1 estimated PS and PBS doses received by the different 
structures expects similar doses to be delivered to the PTV by both modalities. The curves 
which describe the OARs deviate more, with PS being expected to deliver a generally greater 
dose than PBS. The deviations are relatively small, however, and start to converge as the 
volume percentage decreases. The same tendencies are mostly present in the DVH which 
compares the McNamara RBE doses, although the PS curves which describe the OARs show 
a greater relative increase than PBS does. The mean doses received by the PTV is comparable 
for the two modalities, with their difference being below 2% for all patients. The mean doses 
received by the OARs are greater for PS than PBS, with an average difference of around 8-
10% between the two. The maximum doses received by the PTVs deviate by less than 3% on 
average, with the PBS doses being generally greater than the corresponding PS doses. The 
same is true for the maximum doses delivered to the different OARs, where the deviation 
between the modalities on average are below 2%.  
The D50 values for the brainstem are for all patients greater for PS than for PBS, independent 
of the dose calculation technique considered. The differences are below 6% for patient 2 and 
3, while the modalities differ by about 25% for patient 1, whose D50 values are 15-20 Gy less 
than for the other patients. This deviation could be attributed to differences in the location of 
the target volume in relation to the brainstem. The McNamara D50 values of patient 2 and 3 
all exceed the prescribed dose constraint of 54 Gy, while the D50 values of patient 1 are 
beneath. Figure 5.21 shows that the PS D1CC values exceed the PBS values for all patients 
and both dose calculation techniques, with an average deviation of around 3.5%. While the 
RBE1.1 values are all beneath the constraint of 56.1 Gy, all McNamara values exceed this 






The TPS and FLUKA RBE1.1 calculated dose estimates were similar for both treatment 
modalities, with comparable target coverage achieved by the two dose calculation techniques. 
The same was true for the doses deposited to the OARs by the PBS modality, while the 
corresponding PS doses exceeded the TPS doses slightly. This indicates that the FLUKA 
implementation of the PS beamline is correct, and that FLUKA further can be used to explore 
effects from treatment beyond the capability of the TPS, such as LET and RBE based dose 
estimates. While the FLUKA RBE1.1 dose estimates were within 2% of the TPS calculated 
doses for all patients, this was not the case for the McNamara RBE dose estimates: Although 
PBS still demonstrated an increased sparing of healthy tissue compared to PS, the doses 
received by the PTV as well as the OARs went up significantly for all patients when including 
a variable RBE, independent of treatment modality. The D1CC constraint assigned to the 
brainstem core were for all patients exceeded, with the same being true for 2 out of 3 patients 
when considering the D50 constraints. The regions of increased dose deposition agreed well 
with the LETd and RBE distributions, with the mean RBE values within all ROIs exceeding 
1.1. This indicates that the clinical use of an RBE of 1.1 could lead to overdosing of the OARs, 
which for posterior fossa tumors increases the risk of brainstem necrosis. Although the RBE 
values estimated for the PBS modality were either similar or greater than those estimated for 
PS, PBS still provides a better dose conformity. In conclusion, the obtained results indicate 
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